Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID05904548

Vision-MR Ablation Catheter 2.0 for Treatment of Type I Atrial Flutter in the iCMR Environment

Led by Imricor Medical Systems · Updated on 2026-04-13

91

Participants Needed

6

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the safety and effectiveness of radiofrequency (RF) ablation treatment for type I atrial flutter using the Vision-MR Ablation Catheter 2.0 in an interventional cardiac magnetic resonance (iCMR) environment. This prospective, single-arm, multi-center clinical trial aims to gather data on how well this device works and how safe it is for patients with this heart rhythm disorder. The study involves performing type I atrial flutter ablation using the Vision-MR Ablation Catheter 2.0 together with the Advantage-MR EP recorder and stimulator system within the iCMR setting. Participants will receive this treatment during the procedure, which is guided by magnetic resonance imaging to target the affected heart area precisely. Participants will be monitored during and after the procedure to confirm successful blockage of arrhythmia pathways and to track any serious cardiovascular adverse events up to 7 days post-procedure. Further follow-up at 90 days will evaluate the continued absence of atrial flutter episodes and monitor for any serious adverse events throughout the study duration. The trial will assess these clinical outcomes to understand the efficacy and safety of the RF ablation device.

CONDITIONS

Brief Title

Atrial Flutter Ablation in the iCMR

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient indicated for type I atrial flutter ablations with at least 1 documented episode of type I atrial flutter within 6 months (180 days) of enrollment
  • Patient 18 years and older
Not Eligible

You will not qualify if you...

  • Contraindications for MRI procedures
  • Patients who cannot have anti-arrhythmic drugs (class I or class III) prescribed for the treatment of type I atrial flutter stopped on the day of the procedure
  • Previous CTI ablation procedures
  • Myocardial infarction within 60 days of enrollment
  • Current unstable angina
  • Cardiac surgery within 90 days of enrollment
  • Any cerebral ischemic event (including transient ischemic attacks) within 6 months (180 days) of enrollment
  • Thrombocytosis or thrombocytopenia
  • Contraindication to anticoagulation therapy
  • Currently documented intracardiac thrombus or myxoma
  • Implantation of permanent leads of an implantable device in or through the right atrium within 90 days of enrollment
  • Prosthetic valve through which the catheter must pass
  • Interatrial baffle or patch through which the catheter must pass
  • Moderate or severe tricuspid valve regurgitation or stenosis
  • Uncompensated congestive heart failure
  • Active systemic infection
  • Pregnancy or if subject plans to become pregnant during the trial
  • Uncontrolled hyperthyroidism
  • Any other significant uncontrolled or unstable medical condition
  • Enrollment in any concurrent study without Imricor written approval
  • Life expectancy of less than or equal to 2 years (730 days) per physician opinion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Implementation

Duration - Time of procedure

Participants undergo RF ablation for type I atrial flutter using the Vision-MR Ablation Catheter 2.0 in the iCMR environment.

1 procedure visit (in-person)

Follow-up

Duration - 7 days for safety monitoring, up to 3 months for chronic efficacy and safety assessments

Participants are monitored for safety and efficacy after the ablation procedure.

Multiple follow-up visits including a 7-day safety visit and assessments up to 3 months

Trial Site Locations

Total: 6 locations

1

Johns Hopkins University (JHU)

Baltimore, Maryland, United States, 21218

Actively Recruiting

2

University of Virginia (UVA)

Charlottesville, Virginia, United States, 22903

Not Yet Recruiting

3

Virginia Commonwealth University

Richmond, Virginia, United States, 23284

Not Yet Recruiting

4

l'institut Cardiologique Paris Sud (ICPS)

Massy, France, 91300

Actively Recruiting

5

Amsterdam University Medical Center (AUMC)

Amsterdam, Netherlands

Actively Recruiting

6

University Hospital of Vaud (CHUV)

Lausanne, Switzerland, 1011

Actively Recruiting

Loading map...

Research Team

K

Kate Lindborg

J

Jennifer Somerville

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

A Zero Fluoroscopy Maximum Voltage Guided Stepwise Approach ...

Catheter Ablation

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here